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AAV adeno associated virus
Ad adenovirus
Ang angiopoietin
bFGF basic fibroblast growth factor (FGF-2)
cDNA complementary deoxyribonucleic acid
CAM chorioallantoic membrane
CMV cytomegalovirus
E embryonic day
ECM extracellular matrix
FIGF c-fos induced growth factor (VEGF-D)
Flk1 fetal liver kinase 1 (VEGFR-2)
Flt1 fms-like tyrosine kinase 1 (VEGFR-1)
Flt4 fms-like tyrosine kinase 4 (VEGFR-3)
HHV human herpesvirus
HIF hypoxia-inducible factor
HIV human immunodeficiency virus
HSPG heparan sulfate proteoglycan
Ig immunoglobulin
K14 keratin 14
kb kilobase
kD kilodalton
KDR kinase insert domain containing receptor (VEGFR-2)
KS Kaposi’s sarcoma
LYVE-1 lymphatic vessel endothelial hyaluronan receptor-1
MAPK mitogen activated protein kinase
mRNA messenger ribonucleic acid
NP neuropilin
PDGF platelet derived growth factor
PDGF-R PDGF receptor
PI3K phosphatidylinositol 3’-kinase
PlGF placenta growth factor
RTK receptor tyrosine kinase
SC spindle-shaped cell
SLC secondary lymphoid chemokine
SMC smooth muscle cell
Tek tunica interna endothelial cell kinase (Tie-2)
TGF transforming growth factor
Tie tyrosine kinase with Ig and epidermal growth factor homology domains
VE-cadherin vascular endothelial cadherin
VEGF vascular endothelial growth factor
VEGFR VEGF receptor
VPF vascular permeability factor (VEGF)
VRF VEGF related factor (VEGF-B)
VRP VEGF related protein (VEGF-C)
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6Abstract
The blood and lymphatic vessels mediate the passage of fluid, metabolites and cells
between different parts of the body. Although both vessel systems develop in a parallel
manner and share many common features, knowledge of the molecular mechanisms
controlling lymphatic growth has lagged behind the more extensively studied blood
vascular system. The recent discovery of some of the key factors involved in regulating
lymphatic vessel function, as well as the characterization of markers specific for lymphatic
endothelium has enabled more detailed studies on the molecular control of lymphatic
vascular development.
The growth and maintenance of both the blood vascular and the lymphatic vessel systems
is to a large extent mediated by members of the vascular endothelial growth factor (VEGF)
family via their tyrosine kinase receptors (VEGFRs) expressed on endothelial cells. While
blood and lymphatic endothelial cells mostly express different VEGFRs, overlapping
ligand binding patterns have made it difficult to distinguish the signaling pathways
specifically involved in angiogenesis and lymphangiogenesis.
This study was undertaken to differentiate between the functions of VEGFR-2 and
VEGFR-3. To achieve this goal various in vitro and in vivo models were developed. Our
results show that VEGFR-3 specifically mediates lymphangiogenic signals.
7Review of the literature
1. THE BLOOD VASCULAR SYSTEM
The blood vascular system consists of the heart and the blood vessels. The heart muscle
pumps oxygenated blood via arteries and arterioles to the capillaries where bidirectional
exchange of gases and metabolites occurs between blood and tissues. Venules and veins
collect deoxygenated blood from the microvasculature and convey it back to the heart.
Development of the blood vessels
The blood circulatory system is one of the first organ systems to function during
vertebrate development. Embryonic blood vessel formation is guided by poorly
understood developmental cues, which give rise to a vascular network with remarkable
precision and reproducibility with respect to the network basic plan, branching pattern,
hierarchy of differently-sized vessels and dichotomous formation of arteries and veins
(Weinstein 1999).
Vasculogenesis
The first blood vessels develop de novo from endothelial progenitor cells, the angioblasts,
in a process called vasculogenesis. Vasculogenesis initiates when the common ancestor
cells of both endothelial and blood cells, the hemangioblasts, form aggregates termed
blood islands. Cells located in the middle of a blood island develop into hematopoietic
precursors, while the outer cell population develops into angioblasts (Luttun et al. 2002).
One of the key markers defining the angioblast is expression of VEGFR-2 (Kappel et al.
1999). Studies in quail/chick chimeras have shown that basic fibroblast growth factor
(bFGF) mediates the induction of angioblasts from the mesoderm (Poole et al. 2001). In
addition, VEGF and VEGFR-2 influence angioblast differentiation (Shalaby et al. 1995;
Carmeliet et al. 1996; Ferrara et al. 1996), whereas VEGFR-1 suppresses hemangioblast
commitment (Fong et al. 1999). Following commitment to the endothelial lineage,
angioblasts may migrate extensively before assembling into a primitive vascular plexus of
arteries and veins (Carmeliet 2000). Genetic studies in zebrafish have indicated that there
are molecular differences in arterial and venous endothelial cells even before vessel
formation. For example, signals mediated by the receptor Notch1 induce expression of the
basic helix-loop-helix transcriptional repressor gridlock, which commits angioblasts to
arterial fate (Lawson et al. 2001; Zhong et al. 2001). Also members of the ephrin family
and their corresponding Eph receptors are important determinants of arterial and venous
vessel identity during embryonic development (Luttun et al. 2002). These results indicate
that vascular development may be to a large extent genetically predetermined.
Angiogenesis
When the primary vascular plexus has been formed, new capillaries are generated from
the pre-existing vessels in a process termed angiogenesis. In developmental angiogenesis,
new vessels form either by sprouting, splitting or merging of pre-existing vessels (Risau
1997). After the onset of circulation, the emerging vascular plexus is rapidly remodelled
to resemble a more mature system with a hierarchy of large and small vessels.
82. THE LYMPHATIC SYSTEM
The lymphatic system consists of the lymphatic vessels and the lymphoid organs. The
function of the lymphatic vessels is to drain protein-rich lymph and immune system cells
from tissue spaces and return them to the blood circulation. The lymphatic vessels also
absorb lipids from the gut. Lymphatic capillaries are lined with endothelial cells with
overlapping junctions. They lack a continuous basement membrane and are therefore
highly permeable. From the initial capillaries lymph passes to the collecting lymphatic
vessels and finally to the thoracic duct. These larger lymphatics contain contractile
smooth muscle cells, connective tissue and valves to prevent backflow.  Lymphatic
vessels are normally not present in avascular structures like epidermis, cartilage and
cornea, nor in some vascularized organs such as brain, retina and bone marrow (Oliver
and Detmar 2002). Lymphoid organs have important roles in the immune responses.
Figure 1. The “tissue pump” that enables lymph formation. Lymphatic capillaries consist
of one continuous non-fenestrated endothelial cell layer. They are attached to tissue
stroma via elastic fibres called anchoring filaments. When pressure within a tissue
increases, these filaments distend and pull on the endothelial cells opening the gaps
between adjacent cells and allowing fluid to enter. Modified from (Swartz 2001).
Lymphatic markers
The development of lymphatic vessels starts only after the formation of the blood vascular
system (Wigle and Olivier 1999; Wilting et al. 2001). Until recently, the lack of specific
markers has hampered the studies of the mechanisms controlling lymphatic vascular
development. In the early twentieth century, Sabin proposed that isolated primitive lymph
sacs originate from endothelial cells which bud from the veins during embryonic
development, and that the peripheral lymphatic system originates from the primary lymph
sacs by endothelial sprouting (Sabin 1902; Sabin 1904). This view has been widely
Resting ECM strain
9accepted and has recently gained support from genetic analysis of mouse embryos (Wigle
and Olivier 1999). An alternative model suggested that the primary lymph sacs arise
independently in the mesenchyme and only later establish venous connections
(Huntington and McClure 1908). Support for the latter model has been obtained in birds,
where it was proposed that the lymphatics of the early wing buds are not exclusively
derived by sprouting from the lymph sacs but also incorporate lymphangioblasts from the
embryonic mesenchyme (Schneider et al. 1999). A combination of both mechanisms may
therefore contribute to the formation of the lymphatic system.
VEGFR-3
VEGFR-3 was one of the first molecular markers of the lymphatic vessels to be identified
(Kaipainen et al. 1995). VEGFR-3 is a receptor tyosine kinase (RTK) initially expressed
at embryonic day (E) 8.5 of mouse development in the posterior cardinal veins and in
angioblasts of the head mesenchyme (Kaipainen et al. 1995). At E12.5, VEGFR-3 is
expressed both in developing venous and in presumptive lymphatic endothelium, whereas
in adult tissues VEGFR-3 is largely restricted to the lymphatic endothelium (Kaipainen et
al. 1995; Partanen and Paavonen 2001). In addition to lymphatic endothelial cells,
VEGFR-3 is expressed in fenestrated and discontinuous blood vascular endothelia
(Partanen et al. 2000; Saaristo et al. 2000), and in blood capillaries of tumors and chronic
wounds (Partanen et al. 1999; Valtola et al. 1999; Paavonen et al. 2000).
Podoplanin
Podoplanin, a cell surface glycoprotein, has recently been identified as a marker for the
lymphatic vasculature (Breiteneder-Geleff et al. 1999). In humans, podoplanin is
expressed in osteoblastic cells, kidney podocytes, lung alveolar type I cells, and lymphatic
endothelial cells (Wetterwald et al. 1996; Breiteneder-Geleff et al. 1999). Also cultured
lymphatic endothelial cells retain podoplanin expression (Kriehuber et al. 2001).
LYVE-1
LYVE-1 is a receptor for the extracellular matrix glycosaminoglycan hyaluronan (Banerji
et al. 1999). Immunohistochemical analyses have demonstrated LYVE-1 expression on
the surface of endothelial cells of lymphatic vessels (Banerji et al. 1999; Prevo et al. 2001;
Wigle et al. 2002). At E10.5, LYVE-1 is expressed uniformly in the endothelial cells of
the cardinal vein, but by E12.5 its expression becomes restricted to lymphatic endothelial
cells (Wigle et al. 2002). LYVE-1 expression has also been detected in the sinusoidal
discontinuous endothelium and the Kupffer cells of liver (Carreira et al. 2001).
SLC
Secondary lymphoid chemokine (SLC) is a soluble factor released by lymphatic
endothelium, which interacts with the CC chemokine receptor 7 on lymphocytes and
mediates lymphocyte homing to the lymph nodes and the spleen (Gunn et al. 1998; Gunn
et al. 1999). SLC expression is first detectable at around E11.5 (Wigle et al. 2002) and it
is expressed uniformly in adult lymphatic endothelia (Gunn et al. 1998).
Prox-1
The homeobox transcription factor Prox-1 was recently shown to be essential for the
development of the murine lymphatic system, as Prox-1 null mice were found to be
devoid of lymphatic endothelial cells (Wigle and Olivier 1999).  In addition to lymphatic
endothelial cells, Prox-1 is expressed in the lens, heart, liver, pancreas and the nervous
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system (Wigle et al. 1999; Wigle and Olivier 1999; Sosa-Pineda et al. 2000). Both normal
and tumor-associated adult lymphatic endothelial cells express Prox-1 (Wigle et al. 2002).
Development of the lymphatic vessels
Detailed analysis of Prox-1 null mice has led to formulation of a model for early
lymphatic vascular development (Oliver and Detmar 2002). After the initial formation of
blood vascular system, venous endothelial cells become competent to respond to a
lymphatic-inducing signal. The first indication that lymphangiogenesis has begun, at
around E9.5, is the specific expression of Prox-1 in a restricted subpopulation of
endothelial cells located on one side of the anterior cardinal vein. At this stage, LYVE-1
is uniformly expressed in the cardinal vein endothelial cells. Around E10.5, the Prox-1
and LYVE-1 double positive cells start budding and spreading in a polarized manner
(Wigle et al. 2002). These budding lymphatic endothelial cells eventually give rise to the
primary lymph sacs, from which lymphatic vessels then spread to peripheral tissues of the
embryo (Wigle and Olivier 1999). All venular endothelial cells may originally be
bipotent, but upon the asymmetric expression of at least Prox-1 in a restricted cell
population these cells become committed to lymphatic differentiation (Wigle et al. 2002).
Prox-1 activity is not required for initiation of endothelial cell budding from the cardinal
vein, but rather for maintaining it (Wigle and Olivier 1999). As the cells bud in a
polarized manner, they start expressing additional lymphatic endothelial markers such as
SLC (Wigle et al. 2002). Also VEGFR-3 expression is maintained at a high level in the
budding lymphatic endothelial cells, while its expression becomes weaker in the blood
vasculature. The simultaneous expression of LYVE-1, Prox-1, VEGFR-3 and SLC may
indicate irreversible commitment to the lymphatic edothelial cell lineage (Wigle et al.
2002).
Additional lymphangiogenic signals are probably mediated by Ang-2, as genetic deletion
of this factor in the mouse results in abnormal lymphatic patterning and function (Dr.
George Yancopoulos, personal communication). In addition, mice deficient of Net, a
member of the Ets-domain transcription factor family expressed in lymphatic vessels, die
neonatally from insufficient lymph drainage and ensuing chylothorax (Ayadi et al. 2001).
Furthermore, integrin α9β1 seems to be required for proper lymphatic development, as α9
deficient neonates die because of similar lymph drainage problems (Huang et al. 2000).
The latter phenotype may relate to a co-operation between α9β1 and VEGFR-3 signaling
(Wang et al. 2001). However, it is not known how the various molecules indicated in
lymphatic development interact during the formation of the lymphatic vasculature.
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Figure 2. Schematic illustration of the development of the blood and lymphatic vascular
systems. Upper panels: Prespecified arterial (red) and venous (blue) endothelial
precursors proliferate, migrate and coalesce into a primitive capillary network, which
subsequently remodels and expands into a mature hierarchial system of arteries and veins.
Lower panels: during embryonic development, venous endothelial cells respond to
putative lymphangiogenic signals and differentiate into lymphatic endothelial cells
(green). Lymphatic vessels further sprout, expand, and remodel, establishing an open-
ended vessel system that connects to the venous circulation. Alternatively, lymphatic
angioblasts may differentiate directly into lymphatic endothelial cells and form vessels.
Modified from (Alitalo and Carmeliet 2002).
3. MOLECULAR REGULATORS OF ANGIOGENESIS AND
LYMPHANGIOGENESIS
The VEGF family
The members of the vascular endothelial growth factor (VEGF) family play critical roles
in the growth of blood vascular as well as lymphatic endothelial cells. The VEGF family
currently includes six members: VEGF, placenta growth factor (PlGF), VEGF-B, VEGF-
C, VEGF-D and the orf virus VEGF (also called VEGF-E). The VEGFs are secreted
dimeric glycoproteins, all of which contain the characteristic regularly spaced eight
cysteine residues, the cystine knot motif.
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VEGF
VEGF (or vascular permeability factor, VPF) is a major regulator of both physiological
and pathological angiogenesis (Ferrara 1999). In addition, VEGF potently induces
vascular permeability, which is considered important for the initiation of angiogenesis
(Dvorak et al. 1995). Endothelial cell survival in newly formed vessels is VEGF-
dependent (Alon et al. 1995; Benjamin et al. 1999). Consistent with its role in cell
survival, VEGF induces expression of anti-apoptotic proteins in human endothelial cells
(Gerber et al. 1998).
There are multiple VEGF protein isoforms, the most common human ones having subunit
polypeptides of 121, 165, and 189 amino acid recidues (Ferrara 1999). All VEGF
isoforms bind to VEGFR-1 and VEGFR-2. In addition, VEGF165 also binds neuropilin-1
(NP-1). The splice variants differ in their bioavailability: whereas VEGF121 is freely
soluble and does not bind heparin, the larger isoforms contain increasingly basic and
heparin-binding C-terminal domains. A significant fraction of secreted VEGF165 remains
bound to the cell surface and extracellular matrix (ECM), and VEGF189 and VEGF206 are
almost completely sequestered in the ECM (Park et al. 1993). The longer isoforms can be
released by proteolytic cleavage, thus increasing local VEGF concentrations during tissue
growth and remodeling.
VEGF is expressed widely in vertebrate embryos, especially in tissues immediatedly
adjacent to areas of active vessel formation (Weinstein 1999). VEGF expression is critical
for the earliest stages of vasculogenesis, as blood islands, endothelial cells, and major
vessel tubes fail to develop in VEGF knockout embryos (Carmeliet et al. 1996; Ferrara et
al. 1996). The deletion of even a single Vegf allele is lethal, demonstrating a remarkably
strict dose-dependence for VEGF during development (Carmeliet et al. 1996; Ferrara et
al. 1996).
Isoform-specific knockouts of the VEGF gene have also been generated. Mice expressing
exclusively VEGF120 have impaired myocardial contractility, enlarged heart and defective
angiogenesis, and develop ischemic cardiomyopathy (Carmeliet et al. 1999b). In
adddition, endochordal bone formation and retinal vascular patterning are disturbed in
these mice, suggesting that the heparin-binding isoforms of VEGF have functions which
cannot be compensated by VEGF120 (Maes et al. 2002; Stalmans et al. 2002). While mice
expressing only VEGF164 are normal and healthy, those expressing exclusively VEGF188
display impaired arteriolar development (Stalmans et al. 2002).
Transcription of VEGF mRNA is induced by a variety of growth factors and cytokines,
including epidermal growth factor, transforming growth factor-beta1 (TGF-β1) and
keratinocyte growth factor-1 (Ferrara 1999). Importantly, tissue oxygen tension tightly
regulates VEGF expression. Hypoxia rapidly and reversibly induces VEGF expression
through both increased transcription and mRNA stabilization (Plate et al. 1992; Shweiki
et al. 1992; Levy et al. 1996). Hypoxia-induced transcription is mediated by hypoxia-
inducible factor-1 (HIF-1) (Ferrara 1999). Deletion of the hypoxia response element from
the Vegf promoter results in progressive motor neuron degeneration in adult mice
(Oosthuyse et al. 2001).
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PlGF
Alternative splicing of human PlGF transcripts produces two protein isoforms, PlGF-1
(PlGF129) and PlGF-2 (PlGF152) (Maglione et al. 1991; Hauser and Weich 1993; Maglione
et al. 1993). PlGF-2 contains a basic heparin binding peptide insert near its C-terminus
(Hauser and Weich 1993), whereas PlGF-1 is non-heparin binding. In addition to PlGF
homodimers, heterodimers of PlGF-1 and VEGF165
 
have been described (DiSalvo et al.
1995; Cao et al. 1996). While PlGF homodimers bind only to VEGFR-1(Park et al. 1994),
PlGF/VEGF heterodimers bind to soluble VEGFR-2 with high affinity (Park et al. 1994;
Cao et al. 1996). PlGF-2 also binds to neuropilin-1 (Migdal et al. 1998).
PlGF is chemotactic for cultured endothelial cells and monocytes (Clauss et al. 1996), and
purified PlGF-1 induces neovascularization in the rabbit cornea assay and in the chick
chorioallantoic membrane (CAM) assay either as homodimers or as heterodimers with
VEGF165 (Oh et al. 1997; Ziche et al. 1997). Migrating keratinocytes upregulate PlGF
during wound healing (Failla et al. 2000). Loss of PlGF does not affect vasculogenesis or
developmental angiogenesis, but impairs pathological angiogenesis during ischemia,
inflammation, wound healing and tumor growth (Carmeliet et al. 2001). PlGF may
mediate its effects in pathological angiogenesis by mobilizing bone-marrow derived
endothelial precursor cells (Carmeliet et al. 2001).
VEGF-B
VEGF-B (or VEGF related factor, VRF) exists as two alternatively spliced forms, VEGF-
B167 and VEGF-B186, and like PlGF, it can form heterodimers with VEGF (Olofsson et al.
1996a; Olofsson et al. 1996b). VEGF-B186
 
has a somewhat hydrophobic, but O-
glycosylated C-terminus, and is freely soluble, while VEGF-B167 has a strongly basic
heparin-binding C-terminus and is sequestered into ECM. Both VEGF-B isoforms are
ligands for VEGFR-1 and NP-1 (Olofsson et al. 1998; Makinen et al. 1999). VEGF-B is
widely expressed with the highest levels in heart and skeletal muscle (Olofsson et al.
1996a; Aase et al. 1999). Deletion of the VEGF-B gene does not affect vasculogenesis or
angiogenesis, but may result in heart defects (Bellomo et al. 2000; Aase et al. 2001).
VEGF-C
There are no splice variants of VEGF-C (or VEGF related protein, VRP) (Joukov et al.
1996; Lee et al. 1996). Rather, VEGF-C receptor binding profile and affinity are requlated
at the level of proteolytic processing. VEGF-C is produced as a preproprotein with long
N- and C terminal propeptides flanking the VEGF-homology domain. Initial proteolytic
cleavage of the precursor produces a form with intermediate affinity towards VEGFR-3,
but a second proteolytic step is required to generate the fully processed form with a high
affinity for both VEGFR-2 and VEGFR-3 (Joukov et al. 1997). VEGF-C stimulates
migration and mitogenesis of cultured endothelial cells (Joukov et al. 1996; Lee et al.
1996; Joukov et al. 1997; Cao et al. 1998). Fully processed VEGF-C also induces vascular
permeability via VEGFR-2 (Joukov et al. 1997; Joukov et al. 1998).
In the developing mouse embryo VEGF-C mRNA is prominent in regions where
lymphatic vessels develop by sprouting from embryonic veins, and in the developing
mesenterium (Kukk et al. 1996). The adjacent expression patterns of VEGFR-3 and
VEGF-C suggest that VEGF-C acts in a paracrine manner during the formation of the
venous and lymphatic vascular systems (Kaipainen et al. 1995; Kukk et al. 1996). When
applied to mature CAM VEGF-C works as a highly specific lymphangiogenic factor (Oh
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et al. 1997), and overexpression of VEGF-C in the epidermis of transgenic mice results in
dermal lymphatic endothelial proliferation and vessel enlargement (Jeltsch et al. 1997).
However, recombinant VEGF-C promotes angiogenesis in the early CAM where
lymphatic vessels have not yet developed, in avascular mouse cornea and in rabbit
ischemic hindlimb (Cao et al. 1998; Witzenbichler et al. 1998).
VEGF-D
VEGF-D (or c-Fos-inducible mitogen for fibroblasts, FIGF) is also produced as a
preproprotein, and undergoes proteolytic processing in a manner similar to VEGF-C
(Orlandini et al. 1996; Achen et al. 1998; Stacker et al. 1999). Fully processed human
VEGF-D binds to both VEGFR-2 and VEGFR-3, and has been shown to be mitogenic for
cultured microvascular endothelial cells (Achen et al. 1998) and angiogenic in vivo
(Achen et al. 1998; Marconcini et al. 1999).
Interestingly, mouse VEGF-D differs from its human counterpart in at least two aspects.
Mouse VEGF-D is a specific ligand for mouse VEGFR-3 (Baldwin et al. 2001a), and
there are two isoforms of mouse VEGF-D generated by alternative RNA splicing, which
differ in their C-termini (Baldwin et al. 2001b). During mouse embryonic development
both VEGF-D isoforms are expressed in several structures and organs such as limb buds,
heart, lung and skin (Avantaggiato et al. 1998; Farnebo et al. 1999; Baldwin et al. 2001b).
Orf virus VEGF
A gene encoding a VEGF homologue has been discovered in the genome of the
parapoxvirus orf (Lyttle et al. 1994). Interestingly, two strains of the orf virus, NZ2 and
NZ7, encode different variants of the viral VEGF that are only 43% identical with each
other (Lyttle et al. 1994). It is unclear whether the extensive sequence difference between
the two viral proteins represents independent acquisition events from different sources, or
very extensive divergence from a single progenitor.
The VEGF receptors
The VEGFs mediate their signals via high-affinity RTKs, the VEGFRs. Three such
receptors have been identified, VEGFR-1, VEGFR-2 and VEGFR-3. The VEGFRs are
structurally and functionally similar to members of the platelet derived growth factor
(PDGF) receptor family, and form a subfamily within that receptor class (Neufeld et al.
1999; Karkkainen and Petrova 2000). All VEGFRs have seven immunoglobulin (Ig)
homology domains in their extracellular ligand binding part and an intracellular tyrosine
kinase signaling domain split by a kinase insert. Like other receptor tyrosine kinases
(RTKs), the VEGFRs are thought to dimerize and to undergo transphosphorylation upon
ligand binding. Phosphorylated tyrosine residues may serve to control the kinase activity
of the receptor, and to create docking sites for cytoplasmic signaling molecules, which
provide substrates for the kinase.
VEGFR-1
VEGFR-1 (or Flt1) can exist either as a transmembrane glycoprotein or a shorter soluble
form consisting only of the six first extracellular Ig homology domains (Shibuya et al.
1990; De Vries et al. 1992; Kendall and Thomas 1993). Soluble VEGFR-1 has an intron-
derived 31 amino acid stretch in its C-terminus, and is highly conserved between
mammals and birds (Kendall and Thomas 1993; Yamaguchi et al. 2002). In the adult,
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VEGFR-1 is expressed mainly in blood vascular endothelium, vascular smooth muscle
cells and monocytes (Shibuya 2001).
During embryonic development VEGFR-1 is first expressed in the angioblasts at E8.5
(Peters et al. 1993; Fong et al. 1995). Targeted inactivation of the VEGFR-1 gene results
in increased hemangioblast commitment leading to overgrowth of endothelial-like cells
and disorganization of blood vessels (Fong et al. 1995; Fong et al. 1999). Deletion of only
the intracellular domain of VEGFR-1 is compatible with normal vascular development
(Hiratsuka et al. 1998), but impairs tumor angiogenesis associated with overexpression of
VEGFR-1 –specific ligands (Hiratsuka et al. 2001) in agreement with the results from the
PlGF knockout mouse. Also monocyte function is defective in the tyrosine kinase deleted
VEGFR-1 mice, indicating that VEGFR-1 signaling is needed to mediate monocyte
migration in response to VEGF (Hiratsuka et al. 1998).
The tyrosine kinase activity of VEGFR-1 is usually weak, about one tenth that of
VEGFR-2 (Shibuya 2001). This may be due to a repressor sequence in the VEGFR-1
juxtamembrane domain (Gille et al. 2000).
VEGFR-2
There are no reported splice variants for VEGFR-2 (or KDR/Flk1). VEGFR-2 is first
expressed at E7.0 in hemangiogenic lateral plate mesoderm, but later becomes restricted
to the blood islands (Shalaby et al. 1995). Targeted disruption of the VEGFR-2 gene
results in the absence of both blood vessels and blood cells (Shalaby et al. 1995; Shalaby
et al. 1997). Also in the adult VEGFR-2 is expressed both in endothelial cells and in
hematopoietic stem cells (Ziegler et al. 1999).
Although the binding affinity of VEGF for VEGFR-2 is lower than for VEGFR-1, VEGF
is believed to transduce its effects mainly via VEGFR-2. In vitro, several signal
transduction molecules including phosphatidylinositol 3’-kinase (PI3K), phospholipase
Cγ, Src family tyrosine kinases, focal adhesion kinase, Akt/protein kinase B, protein
kinase C, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase
(MAPK), are activated or modified by VEGFR-2 in primary endothelial cells (Matsumoto
and Claesson-Welsh 2001). In vivo, activation of VEGFR-2 leads to expression of
proteases required for basement membrane breakdown, upregulation of specific integrins
expressed on angiogenic endothelium, and in the initiation of endothelial cell proliferation
and migration (Neufeld et al. 1999). VEGFR-2 also mediates vascular permeability,
probably via Src and Yes (Eliceiri et al. 1999; Paul et al. 2001).
VEGFR-3
There are two splice variants of human VEGFR-3 (or Flt4) mRNA, a 4.5 kb transcript and
a more prevalent 5.8 kb transcript (Pajusola et al. 1993). The smaller one is generated by
alternative splicing into the long terminal repeat of a retrovirus integrated between the last
two exons of the VEGFR-3 gene (Hughes 2001). The longer transcript encodes 65
additional amino acid residues and is the major form detected in tissues. After
biosynthesis glycosylated VEGFR-3 is proteolytically cleaved in the fifth Ig homology
domain, but the resulting polypeptide chains remain linked by a disulfide bond (Pajusola
et al. 1994; Lee et al. 1996).
Genetic disruption of VEGFR-3 results in defective remodeling of the primary vascular
plexus, disturbed hematopoiesis, cardiovascular failure and embryonic death by E9.5
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(Dumont et al. 1998; Hamada et al., 2000). However, differentiation of endothelial cells,
formation of primitive vascular networks and vascular sprouting are normal in VEGFR-3
null embryos, indicating that VEGFR-3 function is not necessary for these early stages of
vascular development (Dumont et al. 1998). VEGFR-3 signaling is required for the
formation of the lymphatic vasculature, as lymphangiogenesis can be inhibited with a
soluble VEGFR-3 that competes for ligand binding with the endogenous receptors
(Makinen et al. 2001). Missense mutations in the VEGFR-3 gene resulting in inactivation
of the tyrosine kinase have been linked to primary lymphedema both in humans and in the
mouse (Karkkainen et al. 2000; Karkkainen et al. 2001b).
sVEGFR-1
PlGF
VEGF-B VEGF
VEGF-C
VEGF-D
VEGFR-2 VEGFR-3VEGFR-1
Figure 3. The VEGFs and the VEGFRs. VEGFR-1 and VEGFR-2 are primarly expressed
in blood vascular endothelium, while VEGFR-3 is mostly specific for lymphatic
endothelia.
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Other VEGF binding molecules
Neuropilins
NP-1 and NP-2 are widely expressed cell surface glycoproteins with short cytoplasmic
tails. They bind class 3 semaphorins, secreted molecules mediating repulsive signals
during axon guidance, as well as several VEGF family members (Matsumoto and
Claesson-Welsh 2001). The NPs are believed to be non-signaling and therefore to require
the presence of a signal-transducing receptor in order to mediate their effecfts. By binding
to various VEGFs the neuropilins may act as coreceptors for the VEGFRs and present the
growth factors to their tyrosine kinase receptors in a favourable manner (Soker et al.
1998).
Results from various genetically modified mouse models have revealed that the NPs have
important functions during blood vascular development. Constitutive overexpression of
NP-1 in chimeric mice results in excess capillary formation, blood vessel dilation and
extensive hemorrhaging (Kitsukawa et al. 1995). Mice deficient of NP-1 die at around
E13 with both severe neuronal defects and disturbed blood vascular development
(Kitsukawa et al. 1997; Kawasaki et al. 1999). While no vascular phenotype has been
reported for the NP-2 deficient mice (Chen et al. 2000; Giger et al. 2000), the double
knockout of NP-1 and NP-2 resuls in death at E8.5 with early defects in blood vessel
development, suggesting that compensatory mechanisms operate in the single knockouts
(Takashima et al. 2002). Interestingly, in developing chick embryos endothelial NP-1
expression is mostly restricted to arteries, whereas NP-2 preferentially marks veins,
indicating that the NPs may play a role in determining endothelial arterial and venous
identity (Herzog et al. 2001).
Heparan sulfate proteoglycans
Certain splice isoforms of the VEGFs also bind heparin and heparan sulfate proteoglycans
(HSPG) via distinct heparin binding domains (Gitay-Goren et al. 1992; Olofsson et al.
1996b; Persico et al. 1999). Interestingly, a direct heparin binding site has been
indentified in the extracellular domain of VEGFR-2, and HSPGs are required for VEGF121
binding to VEGFR-1 (Cohen et al. 1995; Dougher et al. 1997), indicating that these
receptors may also associate with cell surface HSPGs. The role of heparin and heparan
sulfates in VEGF-VEGFR function is likely to be complex and to depend on the
interacting molecules and the endothelial cell type involved (Matsumoto and Claesson-
Welsh 2001).
Molecules interacting with VEGF receptors
In addition to receptors that directly bind to the VEGFs, certain cell surface molecules
may participate in VEGF-mediated signaling by interacting with the VEGFRs and
modulating their activity.
VE-cadherin
Vascular endothelial (VE) cadherin is an endothelium-specific transmembrane adhesive
protein involved in forming adherens junctions between endothelial cells. In vitro, VE-
cadherin participates in density-dependent inhibition of endothelial cell growth (Caveda et
al. 1996) by negatively regulating VEGFR-2 signaling (Rahimi and Kazlauskas 1999).
VE-cadherin mediates interactions between β-catenin, PI3K, and VEGFR-2, leading to
activation of Akt and increased expression of the antiapoptotic protein Bcl2 (Carmeliet et
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al. 1999a). In mouse embryos targeted inactivation of VE-cadherin or truncation of its
intracellular domain impairs remodeling and maturation of the primary vascular plexus
due to increased endothelial cell apoptosis, and results in embryonic lethality at E9.5
(Carmeliet et al. 1999a). Interestingly, also VEGFR-3, but not VEGFR-1, associates with
VE-cadherin.
Integrin αvβ3
Integrin αvβ3 is an adhesion molecule that binds to ECM proteins containing an arginine-
glycine-aspartic acid (RGD) peptide motif, such as vitronectin and fibronectin (Eliceiri
2001). αvβ3 interacts with VEGFR-2 in primary endothelial cells and αvβ3 ligation
increases VEGFR-2 kinase activity and enhances VEGF-mediated mitogenic signals
(Soldi et al. 1999; Borges et al. 2000). αvβ3 is expressed in growing, but not in quiescent
blood vessels, and various αvβ3 antagonists, such as blocking antibodies or cyclic RGD
peptides, inhibit angiogenesis (Eliceiri 2001). Surprisingly, pathological angiogenesis is
enhanced in mice lacking integrin β3 alone or in combination with β 5, demostrating that
the functions of αv integrins in the regulation of angiogenesis are still incompletely
understood (Reynolds et al. 2002).
Molecules regulating blood vessel remodeling and stabilization
In addition to the endothelial cells lining the vessel lumen blood vessels contain mural
cells. Depending on their morphology and density the latter are referred to as either
pericytes or smooth muscle cells (SMC).
Figure 4. Endothelial-mural cell interactions. Periendothelial cells (pericytes/PC or
smooth muscle cells/SMC) inhibit proliferation and migration, and induce differentiation,
quiescence, and survival of endothelial cells (EC). In addition, they participate in the
control of vascular tone, establish structural integrity of the vessel wall, mediate
hemostasis, control vascular permeability, and determine vessel remodeling and plasticity.
Modified from (Carmeliet and Collen 2000).
SMC
PC
EC proliferation,
migration
ECEC differentiation,quiescence,
survival
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Pericytes are solitary SMC-like cells associated with arterioles, capillaries and venules,
whereas SMCs form concentric layers around large arteries and veins (Hirschi and
D'Amore 1996). The initial formation of vascular networks proceeds independently of
perivascular cells, but subsequent vessel remodeling and stabilization relies on
mesenchymal-endothelial short range signaling (Lindahl et al. 1998). Several gene
knockout studies have demonstrated that the perivascular cells are essential for
maintaining vascular integrity. These include the disruption of the endothelial cell-
specific RTKs Tie-1 and Tie-2 (Dumont et al. 1994; Puri et al. 1995; Sato et al. 1995), the
Tie-2 ligand angiopoietin (Ang)-1 (Suri et al. 1996), and the PDGF-B/PDGF-B receptor
(PDGF-Rβ) system (Leveen et al. 1994; Soriano 1994; Lindahl et al. 1997; Hellstrom et
al. 1999).
Tie receptors and angiopoietins
There are two members of the Tie class of RTKs, Tie-1 and Tie-2 (or Tek). Both have
extracellular domains consisting of two Ig homology domains, three epidermal growth
factor repeats and three fibronectin-type III homology domains (Loughna and Sato
2001a). The cytoplasmic region of the Tie receptors contains a tyrosine kinase domain
interrupted by a kinase insert. Tie-1 and Tie-2 are predominantly expressed by vascular
endothelial cells (Loughna and Sato 2001a).
Deletion of Tie-2 results in embryonic death between E9.5 and E10.5 as a consequence of
insufficient expansion and maintenance of the primary capillary plexus (Dumont et al.
1994; Sato et al. 1995). In embryos lacking Tie-1, endothelial cell integrity is
compromised, leading to edema, hemorrhages and death between E13.5 and birth (Puri et
al. 1995; Sato et al. 1995). Interestingly, while Tie-2 deficient embryos lack
periendothelial cells pericyte numbers are increased in Tie-1 deficient embryos, indicating
that these receptors are required for establishing normal endothelial cell-pericyte
interactions (Patan 1998). In Tie-1 and Tie-2 double knockout embryos vasculogenesis
proceeds normally, but both receptors are required for angiogenesis during late
embryogenesis and in the adult (Puri et al. 1999). An activating mutation in Tie-2 has
been shown to cause hereditary venous malformations characterized by dilated blood
vessels with deficient smooth muscle cell covering (Vikkula et al. 1996). Abnormally
high Tie-2 activity may also be responsible for the formation of enlarged capillaries in the
skin of mice overexpressing Ang-1 under the keratin 14 (K14) promoter (Suri et al. 1998;
Thurston et al. 1999).
The angiopoietins are ligands for Tie-2 (Davis et al. 1996; Suri et al. 1996; Maisonpierre
et al. 1997; Valenzuela et al. 1999). Whereas Ang-1 and Ang-4 activate Tie-2, Ang-2 and
Ang-3 appear to function as specific antagonists and inhibit Tie-2 signaling. In the
developing embryo, Ang-1 is expressed in the mesenchyme and smooth muscle cells
surrounding the developing vasculature (Davis et al. 1996). Deletion of Ang-1 results in
angiogenic defects very similar to those seen in mice lacking Tie-2, including the absence
of perivascular cells (Suri et al. 1996). Importantly, double knockout of Ang-1 and Tie-1
results in asymmetrical disruption of the right-hand venous system, indicating that distinct
genetic programs control the left-right polarity of the blood vascular system (Loughna and
Sato 2001b). Ang-2 is highly expressed at sites of active vessel remodeling, such as the
ovary and the placenta (Maisonpierre et al. 1997). These expression patterns and the
phenotypes of Tie-2 and Ang-1 knockout mice have led to a model for angiogenic vessel
remodeling, in which Ang-2 is required to block a constitutive stablilizing action of Ang-
1, leading to detachment of perivascular cells that inhibit endothelial cell proliferation,
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and allowing the blood vessels to revert to a more plastic state for initiation of
angiogenesis (Maisonpierre et al. 1997).
PDGFs
Growth factors of the PDGF family are VEGF-related disulfide-bonded dimeric
molecules consisting of homo- and heterodimers of A- and B-polypeptide chains (PDGF-
AA, PDGF-AB and PDGF-BB), or homodimers of C- and D-chains (PDGF-CC and
PDGF-DD) (Heldin et al. 2002). The PDGF isoforms exert their effects by binding to
their RTKs, which consist of α and β subunits. The α subunit binds PDGF A, B and C
chains, while the β subunit binds the B and D chains (Heldin et al. 2002). The different
PDGF isoforms induce different receptor complexes depending on the receptor subunit
types expressed by the target cell.
During the development of the blood vascular system, PDGF-B is expressed in the
endothelial cells of arteries and angiogenic vessel sprouts, while its receptor PDGF-Rβ is
expressed in the perivascular cells of arteries, arterioles and capillaries (Lindahl et al.
1997; Hellstrom et al. 1999). Targeted disruption of PDGF-B or PDGF-Rβ results in loss
of pericytes in several organs, including the central nervous system (Lindahl et al. 1997;
Hellstrom et al. 1999). As a consequence, the blood capillaries of PDGF-B null mice are
dilated, contain increased numbers of endothelial cells and hemorrhage lethally in late
embryogenesis (Lindahl et al. 1997). However, the dependence on PDGF-B/ PDGF-Rβ-
mediated signaling for pericyte and SMC recruitment varies in a tissue-specific manner,
indicating that some pericyte/SMC progenitors are likely to be formed independently of
PDGF-B by endothelial cell-mediated induction of perivascular mesenchymal cells
(Hellstrom et al. 1999). It is therefore believed that newly formed vessels signal to the
surrounding mesenchyme and induce the formation of PDGF-Rβ positive progenitor cells.
Once induced, the PDGF-Rβ positive cells respond to PDGF-B secreted by endothelial
cells by proliferating and migrating along the sprouting capillaries. Differentiated
perivascular cells downregulate PDGF receptors and become refractory to PDGF activity,
but they may retain the ability to revert to their developmental phenotype and be
resensitized to PDGF during physiological or pathological angiogenesis (Lindahl et al.
1998).
Ephrins
In contrast to VEGFs and angiopoietins, the ligands of the large Eph RTK family, ephrins,
do not function as soluble molecules, but are membrane attached via either a
transmembrane domain or a glycolipid anchor (Adams et al. 1999). Ephrin-Eph signaling
between endothelial cells and the surrounding mesenchymal cells has been shown to be
necessary for the correct formation of the cardiovascular system, both in Xenopus laevis
and in the mouse (Adams et al. 1999; Helbling et al. 2000). In early mouse development
ephrin-B2 specifically marks arterial endothelial cells, whereas its receptor EphB4 is
expresed in the venous endothelium (Wang et al. 1998; Gerety et al. 1999). Full deletion
of ephrin-B2, the deletion of its cytoplasmic domain only, or disruption of EphB4 results
in embryonic death with defects in the remodeling of arteries and veins from the primary
capillary plexus (Wang et al. 1998; Gerety et al. 1999; Adams et al. 2001). Bidirectional
signaling between prespecified arterial and venous endothelial cells therefore seems to be
required for normal angiogenesis.
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Gene Null phenotype Lethal at Functions
VEGF Lack of endothelial cells
and blood vessels
E8-9 (-/-)
E11-12 (+/-)
Induction of endothelial cells,
vasculogenesis, angiogenesis
PlGF Impaired pathological
angiogenesis survive Recruitment of EPC?
VEGF-B Heart defects survive ?
VEGFR-1 Increased hemangioblast
commitment E8.5
Modulation of VEGFR-2 activity,
pathological angiogenesis
VEGFR-2 Lack of endothelial
and blood cells E8.5-9.5
Hemangioblast migration,
differentiation, proliferation
VEGFR-3 Defective vascular
remodeling E9.5-10.5
Blood vessel maturation,
lymphatic vessel development and
function
Ang-1 Defective vascular
remodeling E12.5 Blood vessel stabilization
Ang-2
Defective postnatal vascular
remodeling, lymphatic
abnormalities
<P14
Blood vessel destabilization,
lymphatic vessel development and
function
Tie-1 Compromised
endothelial integrity E13.5-P0 EC-pericyte interactions
Tie-2 Defective vascular
expansion and maintenance E9.5-10.5 EC-pericyte interactions
NP-1 Neuronal and
cardiovascular defects E12.5-E13.5
Axon guidance,
VEGF coreceptor
NP-2 Neuronal defects survive Axon guidance,VEGF coreceptor
PDGF-B
Hemorrhaging,
microaneurysms,
loss of perivascular cells
P0 Pericyte recruitment
PDGF-Rβ
Hemorrhaging,
microaneurysms,
loss of perivascular cells
P0 Pericyte maturation,blood vessel stabilization
Ephrin-B2 Defective vascular
remodeling
E11 Establishment of arterial
EC identity
EphB4 Defective vascular
remodeling E10
Establishment of venous
EC identity
Table 1. Summary of knockout studies of ligands and receptors regulating the
development of the circulatory system. For references, see the text.
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Later in embryonic development as well as in the adult Ephrin-B2 continues to selectively
mark the arterial side of the blood vasculature. However, at these later stages its
expression spreads from the endothelial cells to the surrounding smooth muscle cells and
pericytes (Gale et al. 2001; Othman-Hassan et al. 2001; Shin et al. 2001). Interestingly,
ephrin-B2 expression also extends into the capillaries midway between terminal arterioles
and postcapillary venules, thereby challenging the classical conception that capillaries
have neither arterial nor venous identity (Gale et al. 2001; Shin et al. 2001). Ehprin-B2 is
also detected in microvessels in several settings of adult neovascularization including
tumor angiogenesis, contrary to earlier views that such vessels arise exclusively from
postcapillary venules (Gale et al. 2001; Shin et al. 2001).
4. BLOOD VESSEL GROWTH IN THE ADULT
Physiological angiogenesis
A number of physiological processes such as ovulation and menstruation require new
blood vessel growth. Angiogenesis is considered to be the principal mechanism of new
vessel formation in the adult. In addition, recent studies have revealed that endothelial cell
precursors can be incorporated into sites of active blood vessel growth in a
vasculogenesis-type process (Asahara et al. 1997; Asahara et al. 1999a; Takahashi et al.
1999), but the relative contribution of such cells to the forming neovasculature is unclear.
Angiogenesis initiates with vasodilation, a process involving nitric oxide (Carmeliet
2000). Vascular permeability increases in response to angiogenic growth factors, and
extravasating plasma proteins lay down a provisional matrix for migrating endothelial
cells (Dvorak et al. 1995). Periendothelial support cells detach and interendothelial
connections loosen. Activated endothelial cells produce proteases that degrade the
basement membrane. Proteinase action also activates or liberates growth factors
sequestered within the extracellular matrix such as bFGF, VEGF and insulin-like growth
factor-1, thereby further stimulating the angiogenic response (Carmeliet 2000). As a
consequence, endothelial cells migrate into the tissue, proliferate and organize to form
new vessels. The endothelial cells also upregulate expression of PDGF-B to attract
pericytes and SMCs (Lindahl et al. 1998). Signaling by Angiopoietin-1 via Tie-2
stabilises the interaction between the endothelial cells and SMCs, and other factors such
as TGF-β1 further promote vessel maturation by inhibiting endothelial cell proliferation
and stimulating the production of extracellular matrix components (Pepper 1997). Vessels
surrounded by basement membrane and mural cells are regarded as mature.
Pathological angiogenesis
A wide range of diseases, including neoplastic diseases, chronic inflammatory diseases
and diabetic retinopathy are characterized by excessive angiogenesis. In contrast to
physiological angiogenesis, pathological angiogenesis is often induced by inflammation.
Monocytes and macrophages, platelets, mast cells and other leukocytes are attracted to
inflamed sites (Carmeliet 2000). These cells produce angiogenic factors, which stimulate
the growth and migration of endothelial cells and SMCs.
Tumor angiogenesis
Mammalian cells require oxygen and nutrients for survival and therefore need to be
located within the diffusion limit of oxygen (100 to 200 µm) from the nearest blood
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vessel. Therefore, in order to grow to a size beyond a few cubic millimeters tumors must
promote new blood vessel growth. Tumors are believed to switch on angiogenesis by
increasing the expression of angiogenic factors to overcome the inhibitory effects of
endogenous anti-angiogenic factors (Hanahan and Weinberg 2000). Hypoxia plays an
important role in the initiation of tumor neovascularization by upregulating the expression
of many angiogenic growth factors and their receptors (Semenza 2001). Circulating
endothelial precursors may also contribute to tumor angiogenesis (Rafii 2000).
In contrast to normal vessels, tumor vasculature is highly disorganized and tumor blood
flow is chaotic and variable (Baish and Jain 2000). Consequently, hypoxic and acidic
areas often develop within tumors (Helmlinger et al. 1997). Tumor endothelial cells can
be abnormally shaped, overlap each other and have large openings between the cells
(Hashizume et al. 2000). Pericytes may be absent or only losely associated with the
endothelial cells (Morikawa et al. 2002). These defects make tumor blood vessels leaky.
Several different strategies have been designed to inhibit tumor angiogenesis using agents
that interfere with angiogenic ligands, their receptors or downstream signaling, utilize
endogenous angiogenesis ingibitors (Cao 2001), or directly target tumor vasculature
(Arap et al. 2002). Many of these are currently in clinical trials for the treatment of cancer.
However, the efficacy of such therapeutics in human patients is still unclear.
Hypoxia-driven angiogenesis
Hypoxia-stimulated angiogenesis takes place in disorders such as myocardial infarction
and peripheral ischemia. Hypoxia activates HIFs, transcription factors that function as
master switches to induce the expression of several angiogenic factors including VEGF,
nitric oxide synthase, PDGF, Ang-2 and others (Semenza 2001). Hypoxia-driven
angiogenesis may protect the ischemic myocardium (Carmeliet and Jain 2000). However,
it can also cause blindness in premature newborns (Alon et al. 1995) and in diabetic
patients, or hemorrhagic rupture of atherosclerotic plaques.
Arteriogenesis
The term arteriogenesis refers to the growth of pre-existing arteriolar connections into true
collateral arteries that takes place in obstructive arterial disease. Arteriogenesis differs
from angiogenesis both at the cellular and the molecular level (van Royen et al. 2001).
Although angiogenesis probably precedes and accompanies arteriogenesis (Ito et al.
1997), capillary sprouting alone cannot provide enough blood circulation to the
underperfused tissue. Arteriogenesis initiates when shear stress increases in the collateral
pathways upon narrowing of a main artery (van Royen et al. 2001). As a result of
increased collateral flow, endothelial cells are activated, start expressing monocyte
chemotatctic protein and upregulate cell surface receptors involved in monocyte tethering,
rolling and transmigration. Monocytes are subsequently recruited to the site and infiltrate
the vessel wall. They produce cytokines and growth factors which stimulate the
proliferation and recruitment of endothelial cells and SMCs, such as tumor necrosis factor
α, bFGF, PDGF-B and TGF-β1 (Arras et al. 1998). Arteriogenesis results in the formation
of functionally and structurally normal arteries, which are able to sustain circulation and
adapt to changes in physiological demands of blood supply.
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Angioproliferative disease associated with virus infection
Kaposi’s sarcoma
Kaposi’s sarcoma (KS) is an angioproliferative disease occurring in several different
forms that share the same histological traits and are all associated with infection by the
KS-associated herpesvirus or human herpesvirus 8 (HHV8) (Ensoli et al. 2001). KS
generally arises on the skin of the extremities as multiple patches or plaques, but mucous
membranes or internal organs may also be affected. The most aggressive form of KS is
found in human immunodeficiency virus type 1 (HIV-1)-infected individuals.
KS starts as an inflammatory process initiated with T cell activation and systemic
production of inflammatory cytokines (Ensoli et al. 2001). Early stage KS lesions are
infiltrated by immune cells and characterized by intense angiogenesis and proliferating
spindle-shaped cells (SC) of endothelial and macrophage origin, which are considered to
be the tumor cells of KS (Schulz et al. 2002). Inflammatory cytokines reactivate latent
HHV8 in lymphocytes and monocytes. When HHV8-infected leukocytes migrate into KS
lesions, they release the virus, establishing a persistent latent infection of the SC and
endothelial cells (Schulz et al. 2002). These cells start expressing viral latent gene
products that provide growth and antiapoptotic signals.  The long-lasting expression of
HHV8 latency genes together with the deregulated expression of cellular oncogenes
and/or tumor suppressor genes, including c-myc, bcl-2 and p53, are likely to participate in
KS progression toward a real tumor. HHV8 may play a role in KS initiation by inducing
immune responses that paradoxically enchance inflammatory cytokine production and
lesion growth (Ensoli et al. 2001). The Tat protein of HIV-1 acts as a progression factor
for AIDS-KS, and may be responsible for the higher frequency and aggressiveness of KS
in the setting of HIV-1 infection (Barillari and Ensoli 2002).
Orf virus lesions
The orf virus is a double stranded DNA parapoxvirus that infects damaged skin of sheep,
goats and humans causing contagious pustular dermatitis (Haig and Mercer 1998). The
virus replicates in regenerating epidermal keratinocytes and is maintained locally. The
dermal lesions show extensive vascular proliferation, blood vessel dilation and dermal
swelling (Haig and Mercer 1998). Generally, orf virus infections resolve within weeks,
but severe infections that fail to resolve without surgical intervention develop in immune
compromised individuals (Haig 2001). In these cases, the large proliferative lesions have
a tumor-like appearance.
The orf virus genome contains a gene encoding a VEGF homologue (Lyttle et al. 1994).
The viral VEGF gene is expressed early after infection and its removal attenuates the
disease (Savory et al. 2000). Therefore, viral VEGF is a true virulence factor. The
function of viral VEGF is not fully understood, but it may participate in maintaining or
expanding epidermal cells for infection (Haig and Mercer 1998).
Therapeutic angiogenesis
In most clinical settings the natural adaptive responses to poor perfusion are insufficient
and unable to halt the progression of ischemic disease in the myocardium or in the
extremities. The term therapeutic angiogenesis refers to the induced growth of new blood
vessels as a treatment for such diseases. Several angiogenic molecules including various
FGFs and VEGF isoforms have been tested in animal models for treatment of ischemic
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disease, either in the form of recombinant proteins, plasmid DNA or viral vectors (Ferrara
and Alitalo 1999). Also a modified constitutively active form of HIF-1α and a peptide
inhibitor of HIF-1α degradation have been shown to induce angiogenesis in the setting of
experimental ischemia (Li et al. 2000; Vincent et al. 2000).
While VEGF is a potent inducer of angiogenesis it also mediates vascular permeability.
Lower extremity edema is the most commonly reported side-effect after VEGF gene
transfer (Baumgartner et al. 2000). Intravenous injection of adenovirus encoding VEGF
into mouse circulation resulted in widespread tissue edema and death (Thurston et al.
2000). However, VEGF-induced vascular leakage was blocked by simultaneous
administration of adenoviral Ang-1, indicating that multifactorial therapy may be required
for the generation of non-leaky vessels (Thurston et al. 2000).
Ischemia, VEGF and specific cytokines have been shown increase the mobilization of
endothelial progenitor cells from the bone marrow (Asahara et al. 1999b; Takahashi et al.
1999; Kalka et al. 2000a). Endothelial progenitor cells in the systemic circulation home to
sites of neovascularization (Asahara et al. 1999a; Crosby et al. 2000). Ex vivo expanded
endothelial progenitor cells incorporate into angiogenic vessels both in rat myocardium
and in mouse ischemic hindlimb, and VEGF gene transfer into the progenitor cells in
culture augmented the therapeutic effect in a hindlimb ischemia model (Kalka et al.
2000b; Kawamoto et al. 2001; Iwaguro et al. 2002). Endothelial progenitor cell
transplantation, possibly in combination with ex vivo gene transfer, might thus be used to
supplement the endogenous angiogenic response.
5. LYMPHATIC VESSEL GROWTH IN THE ADULT
Physiological lymphangiogenesis
In adult tissues lymphangiogenesis appears to follow but lag behind angiogenesis. The
requirement for lymphatic growth in the setting of angiogenesis can be understood by the
need to drain fluid leaking out of the immature blood vessels. For example, during wound
healing VEGFR-3 positive lymphatic vessels sprout from pre-existing lymphatics into the
granulation tissue (Paavonen et al. 2000). Therefore, lymphangiogenesis is probably an
essential feature of tissue repair and inflammatory reactions in most organs.
Pathological lymphangiogenesis
Tumor lymphangiogenesis and lymphatic metastasis
In many human cancers the lymphatic system serves as the primary route for metastatic
spread of tumor cells, and metastasis to the regional lymph nodes is one of the most
important indicators of tumor aggressiveness (Karpanen and Alitalo 2001). Whereas
lymphatic vessels containing clusters of tumor cells are frequently observed at the
periphery of malignant tumors, it is generally believed that functional lymphatics are
absent within solid tumors (Jain and Fenton 2002). However, intratumoral lymphatic
vessels have been documented in tumor xenografts overexpressing VEGF-C or VEGF-D
(Skobe et al. 2001a; Skobe et al. 2001b; Stacker et al. 2001), and in head and neck
squamous cell carcinomas (Beasley et al. 2002). On the other hand, no intra-tumoral
lymphatic vessels were detected in invasive breast cancer (Jackson et al. 2001) or in mice
overexpressing VEGF-C as a transgene in tumor cells (Mandriota et al. 2001). This
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discrepancy may at least in part be explained by the trapping of pre-existing lymphatic
vessels between the rapidly growing tumor foci in the xenografts.
A critical issue is whether the intratumoral vessels expressing lymphatic markers are
functional lymphatics. Lymphangiography by intravital microscopy has been used to
study lymphatic function in experimental tumors. The results indicate that while
lymphatic vessels in the tumor periphery are perfused and often enlarged, those inside the
tumor mostly appear compressed and non-functional (Leu et al. 2000; Padera et al. 2002).
This may be due to the mechanical stress generated by the neoplastic cells grown within a
confined space, which would compress the lymphatic channels inside the tumors.
VEGF-C-induced tumor lymphangiogenesis and lymphatic metastasis can be inhibited by
adenoviral expression of soluble VEGFR-3, which “traps” available VEGF-C and VEGF-
D (Karpanen et al. 2001). Inhibition of VEGFR-3 with neutralizing antibodies also
suppressed the growth of experimental tumors by destabilizing tumor-associated
angiogenic vessels without affecting the established blood and lymphatic vasculature
(Kubo et al. 2000). Furthermore, tumor lymphatic spread induced by VEGF-D was
blocked with an antibody specific for VEGF-D (Stacker et al. 2001). Therefore, drugs
specifically targeted to peritumoral lymphatic vessels might be used to inhibit lymphatic
metastasis. However, destruction of these vessels could further elevate interstitial pressure
inside the tumor, which is known to interfere with the delivery of anti-cancer agents (Jain
2002).
Lymphedema
Lymphedema is a disorder caused by insufficient lymph drainage, which results in the
build-up of protein rich fluid in tissues causing chronic swelling of the extremities (Witte
et al. 2001). Lymphedema patients also suffer from dermal fibrosis, accumulation of
adipose tissue, impaired wound healing and increased susceptibility to infections (Witte et
al. 2001). Etiologically lymphedema can be divided into two main categories. Primary
lymphedema is a rare developmental disorder characterized by hypoplasia of the
cutaneous lymphatic vessels. Missense mutations in the VEGFR-3 gene that interfere with
VEGFR-3 tyrosine kinase function have been identified in some cases of hereditary,
early-onset lymphedema (Milroy’s disease) (Karkkainen et al. 2000). However, primary
lymphedemas are a heterogenous group of disorders and several other genetic loci have
also been implicated in Milroy’s disease and other lymphedema syndromes. For example,
inactivating mutations in the transcription factor FoxC2 have been reported in
lymphedema distichiasis characterized by congenital lymphedema, a double row of
eyelashes and, in some cases, additional complications such as cardiac defects (Fang et al.
2000). Secondary or acquired lymphedema can develop when lymphatic vessels are
blocked or damaged by infection or radiation therapy, or when lymph nodes are surgically
removed. Secondary lymphedema is a relatively common disorder with estimated 3 to 5
million patients in the USA alone.
A mouse model for Milroy’s disease has been obtained by chemical mutagenesis. Like
some of the human lymphedema patients these Chy mice are heterozygous for a germline
inactivating mutation in the VEGFR-3 tyrosine kinase domain (Karkkainen et al. 2001b).
The Chy mice have hypoplasia of the dermal lymphatic vessels, develop subcutaneous
fluid and demostrate swelling of the paws. In addition, the function and integrity of the
intestinal lymphatic vessels are compromized resulting in accumulation of chylous fluid
in the peritoneal cavity (Karkkainen et al. 2001b).
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Therapeutic lymphangiogenesis
At present, therapeutic options for the management of lymphedema are limited, consisting
mainly of physiotherapy, massage and external compression (Witte et al. 2001). The
discovery of specific genes involved in the regulation of lymphatic function and in the
pathology of lymphedema has led to experimental approaches for treating this disease.
Adenoviral VEGF-C gene transfer into normal mouse skin was shown to result in a strong
lymphangiogenic response (Enholm et al. 2001), and viral VEGF-C gene therapy induced
the growth of functional lymphatic vessels in the skin of the Chy mice (Karkkainen et al.
2001b). However, high levels of VEGF-C also caused blood vascular effects such as
increased vessel leakiness, presumably through the interaction of VEGF-C with VEGFR-
2 expressed on blood vascular endothelium (Saaristo et al. 2002).
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Aims of the study
I Biochemical characterization of the orf virus VEGF variant NZ2
Orf virus lesions feature angiogenesis, vasodilation and dermal swelling. These
characteristics may result from the action of orf virus encoded VEGF homologue, but the
biochemical properties of the viral VEGF were not known. We produced recombinant orf
virus VEGF variant NZ2 and tested it in a variety of assays to study its receptor
specificity and functions.
II Isolation and culture of primary lymphatic endothelial cells
In adult tissues VEGFR-3 is mainly expressed in lymphatic endothelium, but the signaling
pathways activated by VEGFR-3 have been incompletely characterized due to lack of
cultured lymphatic endothelial cells. We isolated primary lymphatic endothelial cells from
mixed cultures of dermal microvascular endothelial cells and studied VEGFR-3
–mediated signals in these cells.
III Characterization of VEGFR-3 in vivo function
VEGF-C and VEGF-D are ligands for VEGFR-3, but they also bind to and activate
VEGFR-2. In order to differentiate between the signals mediated by VEGFR-2 and
VEGFR-3 in vivo, we generated transgenic mice overexpressing VEGF-D or the VEGFR-
3 specific mutant form of VEGF-C, VEGF-C156S (Joukov et al. 1998), under the K14-
promoter and analysed their dermal blood vascular and lymphatic phenotypes.
IV Lymphangiogenic gene therapy specifically targeting VEGFR-3
VEGF-C is known to stimulate lymphangiogenesis in vivo, but high levels of VEGF-C
also induce blood vascular effects (Saaristo et al. 2002). In order to develop a lymphatic-
specific gene therapy approach, we compared lymphangiogenesis induced by VEGF-C
and VEGF-C156S in different in vivo models.
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Materials and Methods
An overview of the methods used in these studies is presented here. For more detailed
information, please refer to the original articles.
Expression and purification of recombinant orf virus VEGF variant NZ2 (I)
A DNA fragment containing nucleotides 4-401 of the VEGF-like gene from orf virus
strain NZ2 was prepared by PCR and inserted into the pEFBOS-I-Flag expression vector.
The protein was expressed transiently in COS cells and recovered from cell culture
medium by anti-Flag chromatography.
Bioassay for VEGFR stimulation (I, II)
Ba/F3 cells expressing chimeric receptors containing the extracellular domains of either
VEGFR-1, VEGFR-2 or VEGFR-3 and the transmembrane and cytoplasmic domains of
the mouse erythropoietin receptor were distributed to 96-well microtiter plates containing
dilutions of the test reagent or medium alone. After 48 h, cell viability was determined.
Endothelial cell apoptosis and migration assays (II)
For the apoptosis assay, 70 000 cells were seeded into 24-well plates. Treatments were
carried out in duplicate and apoptosis was detected by measuring cytoplasmic histone-
associated DNA fragments.
Migration assays were performed in a 48-well chemotaxis Boyden chamber. The cells
were suspended in serum-free medium, 10 000 cells per well were allowed to migrate for
six hours at +37°C, and the number of migrated cells was counted.
Receptor binding and activation analysis (I, III, IV)
The binding of various VEGFs to human and mouse receptors was assessed by
precipitation from metabolically labelled transfected cell conditioned medium using
soluble recombinant receptor-Ig fusion proteins. The complexes were adsorbed to protein-
A sepharose and analysed by SDS-PAGE and autoradiography.
Receptor stimulation was carried out using serum-starved cells. The growth factors were
diluted in serum-free media and the cells were stimulated for ten minutes at +37°C. Cell
lysates were immunoprecipitated with antisera specific for VEGFR-2 or VEGFR-3 and
analysed for tyrosine phosphorylation with Western blotting using phosphospecific
antibodies.
Isolation of lymphatic and blood vascular endothelial cells (II)
Monoclonal antibodies against VEGFR-3 (clone 2E11) or polyclonal affinity-purified
anti-podoplanin antibodies were used to isolate lymphatic endothelial cells from cultures
of human microvascular endothelial cells. MACS colloidal super-paramagnetic
MicroBeads conjugated to rat anti-mouse IgG1 or goat anti-rabbit IgG antibodies, MACS-
MS separation columns and MiniMACS separator were used for cell sorting.
Generation of recombinant viruses (IV)
For the adenovirus constructs, full length human VEGF-C and VEGF-C156S cDNAs
were cloned under the CMV promoter. Replication-deficient, E1-E3 deleted adenoviruses
were produced in 293 cells and concentrated by ultracentrifugation. Adenovirus encoding
nuclear-targeted LacZ was used as a control virus. For the AAV constructs, full length
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human VEGF-C and VEGF-C156S were cloned under the CMV promoter and
recombinant AAVs (serotype 2) were produced as previously described (Karkkainen et al.
2001b). AAV encoding enhanced green fluorescent protein was used as a control.
Mouse models (III, IV)
For generation of transgenic mice, the cDNAs encoding full-length human VEGF-D and
VEGF-C156S were cloned into a human K14 promoter expression cassette (Vassar et al.
1989) and injected into fertilized mouse oocytes of the strain FVB/NIH. Several
independent inbred transgenic lines were generated and those with high levels of
transgene mRNA expression were used for phenotype analysis. The generation of the
K14-VEGF-C mice has been described previously (Jeltsch et al. 1997).
Immunodeficient athymic NMRI nu/nu mice were used for the initial studies of viral
VEGF-C and VEGF-C156S gene transfer. The Chy lymphedema mice were used for
analyzing the therapeutic potential of VEGF-C156S. VEGFR-2+/LacZ (Shalaby et al.
1995) and VEGFR-3+/LacZ (Dumont et al. 1998) mice were used for the analysis of
VEGFR-2 and VEGFR-3 expression in the lymphatic vessels.
Analysis of blood and lymphatic vessels (III, IV)
Blood vessels in whole mount preparations of mouse skin were visualised either by
biotinylated Lycopersicon esculentum lectin or by immunohistochemical staining using
antibodies against PECAM-1. Lymphatic vessels were visualised either with antibodies
against VEGFR-3 or by X-gal staining in heterozygous VEGFR-3+/LacZ mice. Whole
mount analysis results were confirmed by staining tissue sections with antibodies against
mouse podoplanin, VEGFR-2, VEGFR-3, LYVE-1, and PECAM-1.
The effects of VEGF-C and VEGF-C156S on blood vessel permeability were studied by
comparing vascular leakage in infected ear skin after an intravenous injection of Evans
blue dye. Statistical analysis was performed using Student’s t-test. The function of skin
lymphatic vessels was analysed by fluorescent microlymphangiography or by Evans blue
injection.
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Results and discussion
I. Orf virus VEGF variant NZ2 is a ligand for VEGFR-2 and NP-1
Amino acid sequence alignment of the orf virus VEGF variant NZ2 with other VEGF
family members revealed that it carries the characteristic cysteine knot motif present in all
mammalian VEGFs. Recombinant Flag-tagged orf virus VEGF was produced in
mammalian cells and determined to be a glycosylated disulfide-linked homodimer with a
monomeric molecular mass of approximately 25 kD. Orf virus VEGF bound to soluble
VEGFR-2 and induced VEGFR-2 tyrosine phosphorylation in transfected cells, but failed
to bind to VEGFR-1 or VEGFR-3. In addition, it bound to soluble NP-1. Orf virus VEGF
was mitogenic for primary endothelial cells in culture and induced vascular permeability
in the Miles assay.
These results demonstate that orf virus VEGF is a biologically active member of the
VEGF family with a unique receptor binding profile. Interestingly, the amino acid
residues which in VEGF have been determined to be critical for VEGFR-1 binding are
partially conserved in orf virus VEGF, whereas those involved in binding to VEGFR-2
are not (Keyt et al. 1996). This suggests that the VEGFR-2 binding sites for orf virus
VEGF and VEGF differ.
The orf virus VEGF variants NZ7 and D1701 have also been biochemically characterized
(Ogawa et al. 1998; Meyer et al. 1999). Both were shown to be specific ligands for
VEGFR-2, and to induce endothelial cell proliferation and vascular permeability (Ogawa
et al. 1998; Meyer et al. 1999). Orf virus VEGF resembles VEGF121 in that both lack
heparing binding affinity, but whereas VEGF121 has much reduced mitogenic activity in
comparison to VEGF165, orf virus VEGF potency was similar to that of VEGF165 . This
may be due to orf virus VEGF-induced interaction between NP-1 and VEGFR-2 resulting
in enhanced VEGFR-2 mitogenic signaling. Phylogenetically orf virus VEGF variants
constitute a novel subfamily of the VEGF growth factors, distinct but most closely related
to VEGF (Meyer et al. 1999). All orf virus VEGFs have a conserved C-terminal
threonine- and proline-rich motif that is not present in any mammalian VEGF (Meyer et
al. 1999). The variants NZ2 and D1701 are closely related, but NZ7 represents an
exceptionally divergent sequence.
II VEGFR-3 mediates growth, survival and migration in cultured lymphatic
endothelial cells
Based on differential expression of cell surface markers, cultured human dermal
microvascular endothelial cells were shown to consist of distinct populations of lymphatic
and blood vascular endothelial cells. Antibodies against the lymphatic-specific markers
VEGFR-3 and podoplanin were used to isolate lymphatic endothelial cells from these
cultures. In the absence of added growth factors the lymphatic endothelial cells did not
proliferate whereas VEGF and VEGF-C promoted the growth of these cells. In apoptosis
assays VEGF, VEGF-C and VEGF-C156S protected the lymphatic endothelial cells from
serum starvation-induced apoptosis, while only VEGF and VEGF-C mediated survival of
the VEGFR-3 negative blood vascular endothelial cells. Both cell populations were shown
to express VEGFR-2. VEGFR-3 signaling was found to induce via PI3K the activation of
the serine-threonine kinase Akt, a major mediator of cell survival. VEGFR-3 stimulation
also induced p42/p44 MAPK activation, although MAPK phosphorylation was much
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stronger in cells treated with the VEGFR-2 ligands VEGF and VEGF-C. MAPK
activation was mediated by PKC, as a specific inhibitor of PKC completely abolished
p42/p44 activation induced by VEGF, VEGF-C and VEGF-C156S. Whereas both blood
vascular and lymphatic endothelial cells migrated towards VEGF and VEGF-C, only the
VEGFR-3 positive lymphatic endothelial cells migrated towards VEGF-C156S in the
Boyden chamber assay.
This was the first time when specific molecular markers were used to isolate lymphatic
endothelial cells. Our results demonstrate that VEGFR-3 stimulation alone is sufficient to
protect lymphatic endothelial cells from apoptosis, and to increase their growth and
migration. VEGFR-3 also induced two signaling cascades important for cell proliferation
and survival, the PI3K mediated Akt phosphorylation and the PKC-dependent p42/p44
MAPK activation. In vivo, inhibition of VEGFR-3 signaling causes regression of the
developing lymphatic vessels due to increased lymphatic endothelial apoptosis, further
demonstrating the importance of VEGFR-3 mediated survival signals (Makinen et al.
2001).
An independent study demonstrating the isolation of primary lymphatic endothelial cells
using podoplanin as a specific marker was also published (Kriehuber et al. 2001). In
accordance with our findings, Kriehuber and co-workers demonstrated that only the
lymphatic cell population expresses substantial levels of VEGFR-3. In addition, they
showed that the lymphatic endothelial cells constitutively secrete SLC.  On the other
hand, while in our study LYVE-1 was expressed only in a subset of the lymphatic
endothelial cells, Kriehuber and co-workers observed uniform LYVE-1 expression on the
lymphatic endothelial population. Importantly, in both our work and in that of Kriehuber
and co-workers’, blood vascular endothelial cells were the sole source of VEGF-C. In
vivo, the regeneration of lymphatics after injury follows that of the blood vessels with a
delay (Paavonen et al. 2000), but the reason for this has remained enigma. In the light of
these data it seems that the re-established blood vasculature may directly induce
lymphatic endothelial proliferation and lymphangiogenesis by secreting VEGF-C.
III VEGFR-3 mediates lymphangiogenesis in transgenic mice
Human VEGF-C156S was shown to be a specific ligand for mouse VEGFR-3, whereas
human VEGF-D binds to both mouse VEGFR-2 and VEGFR-3.  We established
transgenic mouse lines expressing high levels of human VEGF-D or VEGF- C156S under
the K14 promoter, which directs transgene expression to the basal keratinocytes. In both
the K14-VEGF-D and the K14-VEGF-C156S mice, large spaces were detected in the
upper epidermis. These spaces were lined with endothelium positive for the lymphatic
markers VEGFR-3 and LYVE-1, and were devoid of red blood cells. In whole mount
analysis, the skin blood vasculature of both the K14-VEGF-D and the K14-VEGF-C156S
mice appeared normal, whereas the superficial lymphatic capillaries were greatly dilated.
These hyperplastic lymphatic capillaries were, however, functional in that they took up
and transported fluorescent dextran and Evans blue dye after an intradermal injection.  We
did not detect transgene-encoded proteins in systemic circulation, and the lymphatic
phenotype of distant organs remained unchanged. Mating the K14-VEGF-D and the K14-
VEGF-C156S mice with mice expressing soluble VEGFR-3 under the K14 promoter
completely abolished the lymphatic hyperplasia.
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Our results demostrate that signaling via VEGFR-3 alone is sufficient for
lymphangiogenesis in vivo. Lymphatic dilation in the skin of the K14-VEGF-D and K14-
VEGF-C156S mice is unlikely to be the result of increased vascular leakage, as both
VEGF-D and VEGF-C156S have been reported to be inactive in the Miles permeability
assay  (Achen et al. 1998; Joukov et al. 1998). Importantly, even though VEGF-D has
been reported to be angiogenic in the rabbit avascular cornea (Marconcini et al. 1999), we
observed no VEGF-D-induced blood vascular effects. The lack of angiogenesis in our
transgenic model may relate to incomplete proteolytic processing of VEGF-D in the skin,
and therefore reduced affinity towards VEGFR-2. As no systemic effects were detected
in either mouse strain, VEGF-D and VEGF-C156S can be considered for use in local
lymphangiogenic gene therapy .
VEGF isoforms VEGF164 and VEGF120 have also been transgenically overexpressed in the
epidermis (Detmar et al. 1998; Larcher et al. 1998). In these mice the numbers of
cutaneous blood capillaries and vascular permeability were highly increased. Despite
substantial edema, no changes in the skin lymphatic vasculature were detected in the K14-
VEGF164 mice (Detmar et al. 1998; Thurston et al. 1999). These findings indicate that
VEGFR-2 activation even in combination with increased intestitial fluid pressure is not
sufficient for new lymphatic vessel growth, but that VEGFR-3 mediated signals are
required.
IV VEGFR-3 mediates therapeutic lymphangiogenesis
In order to compare the consequences of VEGF-C156S and VEGF-C gene transfer in
vivo, the lymphatic phenotypes of K14-VEGF-C156S and K14-VEGF-C transgenic
embryos heterozygous for LacZ in the VEGFR-3 locus were first analysed. At E14.5, the
cutaneous lymphatics of both types of embryos were clearly hyperplastic, but whereas
VEGF-C156S mainly induced enlargement of the pre-existing lymphatics, VEGF-C
strongly stimulated lymphatic sprouting. Recombinant  adenoviruses (Ad) and adeno
associated viruses (AAV) encoding human VEGF-C or VEGF-C156S were generated and
shown to produce active transgene-encoded proteins in infected cell cultures. To detemine
whether the effects of VEGF-C156S and VEGF-C are recapitulated in adult
lymphangiogenesis, viruses encoding VEGF-C156S or VEGF-C were injected
intradermally into ears of immunocompromised mice.  Both factors mediated lymphatic
vessel growth, but as in the transgenic mouse models, the response to VEGF-C156S was
mostly lymphatic hyperplasia whereas VEGF-C induced intensive lymphatic sprouting.
Analysis of the blood vascular phenotypes after AdVEGF-C156S or AdVEGF-C injection
revealed that whereas VEGF-C induced blood vessel tortuosity, enlargement, and leakage,
minimal blood vascular changes resulted from VEGF-C156S. The consequence of an
intravenous injection of AdVEGF-C was dose-dependent accumulation of thoracic fluid
and in some cases death, but systemic AdVEGF-C156S had no adverse effects. AAV-
mediated VEGF-C156S and VEGF-C gene transfer in the skin of lymphedema mice
induced the formation of functional lymphatic vessels that persisted for at least eight
months. In the adult lymphatic vasculature VEGFR-3 was most strongly expressed by the
initial lymphatic capillaries, while VEGFR-2 was present in highest amounts in the
collecting lymphatic vessels. Although the lymphatic capillaries were highly hyperplastic
in the K14-VEGF-C mice, their collecting lymphatic vessel phenotype was normal.
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The mechanisms of lymphangiogenesis appear to be very similar to angiogenesis in that
both involve vessel enlargement, sprouting and splitting. Although both VEGF-C156S
and VEGF-C induced an increase in skin lymphatic vascularity, their effects on the
lymphatic vessels differed. Our results indicate that VEGFR-2 activation may be required
for efficient induction of lymphatic sprouting. While systemic injection of AdVEGF-C led
to greatly and sometimes fatally increased vascular permeability, we observed minimal
blood vascular effects with AdVEGF-C156S. Gene transfer using AAV vectors resulted
in a more controlled and longer-lived lymphangiogenic response than was achieved with
acute high-level transgene expression from the adenoviral vectors, indicating that AAV
may be more suitable for future human lymphangiogenic gene therapy. The differential
expression of VEGFR-3 and VEGFR-2 on lymphatic capillaries and collecting vessels
may indicate differences in lymphatic endothelial cell function, and underscores the
importance of developing strategies to specifically target various types of lymphatic
vessels.
Angiogenic gene therapy has raised concerns about the potential stimulation of growth of
dormant tumors due to increased tumor angiogenesis in response to elevated systemic
VEGF. Some animal experiments have also indicated that instead of stimulating
angiogenesis constant delivery of high levels of VEGF can result in the development of
vascular malformations or hemangiomas (Springer et al. 1998; Lee et al. 2000; Pettersson
et al. 2000; Dor et al. 2002). Therefore brief duration and low level of localised transgene
expression are requirements for safe angiogenic gene therapy. For lymphatic-specific
therapy the safety margin will probably be wider, and VEGF-C156S gene transfer thus
seems like an attractive choice for patients with lymphatic hypoplasia, dysfunction and
edema. However, as tumor induced lymphangiogenesis has been associated with
enhanced metastasis to the lymph nodes, the risk of tumor dissemination needs to be
carefully evaluated.
VEGF-C156S
Figure 5. Skin lymphatic vessels of E14.5 VEGFR-3+/LacZ embryos visualized by
β-galactosidase staining. Overexpression of VEGF-C156S or VEGF-C increases skin
lymphatic vascularity, but their lymphangiogenic mechanisms differ.
VEGF-C Control
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Concluding remarks
The blood and lymphatic vessel systems co-operate in a tightly regulated manner to
maintain tissue homeostasis. The VEGFRs govern many aspects of the growth and
maintenance of these two vessel systems, both during embryonic development and
physiological and pathological responses in the adult. While VEGFR-1 and VEGFR-2
mainly orchestrate blood endothelial cell responses in angiogenesis, VEGFR-3 plays a
major role in lymphangiogenesis.
There is reason to believe that different endothelial cells express specific sets of receptors
depending on their organ of origin, vessel type and endothelial activation state. Therefore,
they are likely to respond differently to specific stimuli. Physiological angiogenesis
involves a wide spectrum of agents with roles in certain aspects of vessel formation, such
as branching or fusion. Better understanding of the molecular processes involved in
regulation of the various stages of blood and lymphatic vessel growth will undoubtedly
contribute to the design of improved treatment strategies for disorders involving
angiogenesis and lymphangiogenesis.
To date, VEGF-C and VEGF-D are the only known growth factors capable of promoting
lymphatic vascular growth, and are therefore being considered for use in therapeutic
lymphangiogenesis. Understanding the molecular mechanisms behind various forms of
lymphatic disease will allow the development of specific treatments. The results on
experimental therapeutic lymphangiogenesis for hereditary lymphedema using VEGF-
C156S are encouraging, but as for proangiogenic therapy, combinations of growth factors
may be required for the creation of a functional and stable lymphatic vessel network.
Future clinical trials will judge the therapeutic potential of these molecules in man. Also
the existence of circulating or tissue resident lymphangioblasts is still an unresolved issue.
Such lymphatic endothelial precursors could potentially provide a major input for the
generation of new lymphatic vessels.
Figure 6. VEGFR-2, VEGFR-3 and their ligands.
VEGF +  -
VEGF-C + +
VEGF-D + +
VEGF-C156S  - +
Orf VEGF +  -
VEGFR-2 VEGFR-3
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